The Use of Opioids for Breakthrough Pain in Acute Palliative Care Unit by Using Doses Proportional to Opioid Basal Regimen
暂无分享,去创建一个
[1] S. Mercadante. Breakthrough pain: On the road again , 2009, European journal of pain.
[2] G. Zeppetella. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. , 2008, Journal of pain and symptom management.
[3] A. Davies,et al. An observational study of oncology patients' utilization of breakthrough pain medication. , 2008, Journal of pain and symptom management.
[4] S. Mercadante,et al. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. , 2008, Journal of pain and symptom management.
[5] S. Mercadante,et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain , 2007, British Journal of Cancer.
[6] J. Farrar,et al. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. , 2007, Journal of palliative medicine.
[7] J. Farrar,et al. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. , 2006, Journal of pain and symptom management.
[8] S. Mercadante,et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. , 2004, Journal of pain and symptom management.
[9] R. Portenoy,et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®) , 2001, Pain.
[10] E. Kalso,et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations , 2001, British Journal of Cancer.
[11] Jesse A. Berlin,et al. Defining the clinically important difference in pain outcome measures , 2000, PAIN.
[12] Paul Jacobsen,et al. Breakthrough pain: characteristics and impact in patients with cancer pain , 1999, Pain.
[13] R. Portenoy,et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study , 1999, PAIN.
[14] M. Simmonds,et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Farrar,et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. , 1998, Journal of the National Cancer Institute.
[16] R. Portenoy,et al. Breakthrough pain: definition, prevalence and characteristics , 1990, Pain.